melatonin has been researched along with Intraocular Pressure in 49 studies
Intraocular Pressure: The pressure of the fluids in the eye.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study showed that 3 mg Sublingual melatonin premedication for patients undergoing cataract surgery under topical anesthesia reduced patients' anxiety scores, pain score, and IOP." | 9.69 | The Effect of Melatonin on Analgesia, Anxiety, and Intraocular Pressure (IOP) in Cataract Surgery Under Topical Anesthesia. ( Abdelbasset, WK; Golabi, P; Haki, BK; Komilzhonovich, IN; Mahmodi, H; Morwati, S; Motarjemizadeh, Q; Rahmani, N; Sane, S; Suksatan, W; Zaman, GS, 2023) |
| "To evaluate the effects of long-term (30-day) oral administration of melatonin on tear production, intraocular pressure (IOP), and concentration of melatonin in the tears and serum of healthy dogs." | 9.51 | Effects of long-term oral administration of melatonin on tear production, intraocular pressure, and tear and serum melatonin concentrations in healthy dogs. ( Abdous, A; Alagha, HE; Faghihi, H; Fazio, F; Giannetto, C; Omidi, R; Ostadhasan, H; Piccione, G; Rajaei, SM, 2022) |
| "To evaluate the effect of a new nutritional supplement based on melatonin on the intraocular pressure (IOP) in normotensive subjects." | 9.34 | Effect of nutritional supplement based on melatonin on the intraocular pressure in normotensive subjects. ( Bodas-Romero, J; Carracedo-Rodríguez, G; Martínez-Águila, A; Pintor, J; Rodriguez-Pomar, C; Sanchez-Naves, J, 2020) |
| "To determine the effect of orally administered melatonin on the intraocular pressure (IOP) of ophthalmologically normal dogs." | 9.30 | Effect of orally administered melatonin on intraocular pressure of ophthalmologically normal dogs. ( Dees, DD; Millichamp, NJ; Scott, EM; Vallone, LV; Visser, HE, 2019) |
| "Melatonin significantly reduced the anxiety scores (median, interquartile range) from 5 and 5-3 to 3 and 2-4 after premedication and to 3 and 2-3 during surgery and to 0 and 0-1 postoperatively before discharge from the recovery room." | 9.17 | The effects of melatonin on anxiety and pain scores of patients, intraocular pressure, and operating conditions during cataract surgery under topical anesthesia. ( Khezri, MB; Merate, H, 2013) |
| "Melatonin significantly reduced the anxiety scores (median, interquartile range) from 5, 3." | 9.14 | Melatonin provides anxiolysis, enhances analgesia, decreases intraocular pressure, and promotes better operating conditions during cataract surgery under topical anesthesia. ( Ismail, SA; Mowafi, HA, 2009) |
| "We studied the effect of orally administered melatonin on intraocular pressure in humans." | 9.06 | Effect of melatonin on intraocular pressure. ( Krause, G; Lewy, AJ; Samples, JR, 1988) |
| "To study the levels of melatonin in the aqueous humour of normotensive and hypertensive intraocular pressure (IOP) patients and to compare them to an animal model of glaucoma." | 7.85 | Elevated intraocular pressure increases melatonin levels in the aqueous humour. ( Alkozi, H; Carracedo, G; de Lara, MJ; Fonseca, B; Martinez-Aguila, A; Pintor, J; Sánchez-Naves, J, 2017) |
| "Melatonin is a pineal hormone that has a capacity to lower intraocular pressure; it exhibits neuroprotective and antioxidant properties that make it possible to use melatonin in the therapy of glaucoma." | 7.85 | [Novel agonists of melatonin receptors as promising hypotensive and neuroprotective agents for therapy of glaucoma]. ( Beznos, OV; Chesnokova, NB; Grigoryev, AV; Lozinskaya, NA; Volkova, MS; Zaryanova, EV; Zefirov, NA, 2017) |
| " Using both control C57BL/6J and glaucomatous DBA/2J mice as well as TonoLab tonometry, this study evaluated the effect of melatonin and 5-methoxycarbonylamino-N-acetyltryptamine (5-MCA-NAT) when glaucomatous pathology was fully established and compared pharmacological behavior in treated mice versus control mice." | 7.83 | Effect of Melatonin and 5-Methoxycarbonylamino-N-Acetyltryptamine on the Intraocular Pressure of Normal and Glaucomatous Mice. ( Fonseca, B; Martínez-Águila, A; Pérez de Lara, MJ; Pintor, J, 2016) |
| "Melatonin is currently considered a promising drug for glaucoma treatment because of its ocular hypotensive and neuroprotective effects." | 7.79 | Melatonin and its analog 5-methoxycarbonylamino-N-acetyltryptamine potentiate adrenergic receptor-mediated ocular hypotensive effects in rabbits: significance for combination therapy in glaucoma. ( Crooke, A; Huete-Toral, F; Martín-Gil, A; Martínez-Águila, A; Pintor, J, 2013) |
| "We explored the melatonin influence on the level of amino acid neurotransmitters of the retina in glaucoma neuropathy in rats." | 7.79 | [Protective action of melatonin in experimental glaucoma in rats]. ( Mykheĭtseva, IM, 2013) |
| "In the search for new compounds to reduce intraocular pressure (IOP), with fewer side effects, we have found that agomelatine, a melatonin analogue, can reduce IOP being, therefore, interesting for the treatment of ocular hypertension and glaucoma." | 7.79 | Melatonin analogue agomelatine reduces rabbit's intraocular pressure in normotensive and hypertensive conditions. ( Bergua, A; Fonseca, B; Martínez-Águila, A; Pintor, J, 2013) |
| "Melatonin, the MT(2) melatonin receptor agonist IIK7 [N-butanoyl-2-(2-methoxy-6H-isoindolo[2,1-a]indol-11-yl)ethanamine], and the putative MT(3) melatonin receptor agonist 5-MCA-NAT [5-methoxycarbonylamino-N-acetyltryptamine] have previously been shown to reduce intraocular pressure (IOP) in ocular normotensive rabbits." | 7.77 | Design of novel melatonin analogs for the reduction of intraocular pressure in normotensive rabbits. ( Alarma-Estrany, P; Guzman-Aranguez, A; Huete, F; Pelaez, T; Peral, A; Pintor, J; Plourde, R; Yerxa, B, 2011) |
| " We examined the ability of melatonin and the selective MT(3) receptor agonist, 5-methoxycarbonylamino-N-acetyltryptamine (5-MCA-NAT), to modify intraocular pressure in rabbits." | 7.71 | Involvement of melatonin MT(3) receptors in the regulation of intraocular pressure in rabbits. ( Hoyle, CH; Martin, L; Pelaez, T; Peral, A; Pintor, J, 2001) |
| "Melatonin injected into the vortex vein of a rabbit eye produced an increase in intraocular pressure (IOP) which lasted for up to 5 h." | 7.68 | Effects of melatonin and haloperidol given via vortex vein on the intraocular pressure. ( Chiou, GC; Li, BH; Rohde, BH, 1993) |
| "Melatonin is a promising substance to ameliorate glaucoma-associated compromised circadian rhythms, sleep, mood, and retinal cells function." | 7.01 | Melatonin mitigates disrupted circadian rhythms, lowers intraocular pressure, and improves retinal ganglion cells function in glaucoma. ( Astakhov, SY; Cornelissen, G; Gubin, D; Kabitskaya, Y; Kolomeichuk, S; Malishevskaya, T; Neroev, V; Weinert, D; Yuzhakova, N, 2021) |
| "Melatonin is a hormone secreted into the blood mainly from the pineal gland allowing the entrainment of the circadian rhythms of several biological functions." | 6.48 | Update in glaucoma medicinal chemistry: emerging evidence for the importance of melatonin analogues. ( Colligris, B; Crooke, A; Pintor, J, 2012) |
| "This study showed that 3 mg Sublingual melatonin premedication for patients undergoing cataract surgery under topical anesthesia reduced patients' anxiety scores, pain score, and IOP." | 5.69 | The Effect of Melatonin on Analgesia, Anxiety, and Intraocular Pressure (IOP) in Cataract Surgery Under Topical Anesthesia. ( Abdelbasset, WK; Golabi, P; Haki, BK; Komilzhonovich, IN; Mahmodi, H; Morwati, S; Motarjemizadeh, Q; Rahmani, N; Sane, S; Suksatan, W; Zaman, GS, 2023) |
| "The treatment with melatonin significantly decreased clinical signs and prevented the reduction in IOP induced by LPS." | 5.38 | Therapeutic benefit of melatonin in experimental feline uveitis. ( Aba, MA; Del Sole, MJ; Fernandez, DC; Rosenstein, RE; Sande, PH; Sarmiento, MI, 2012) |
| "Glaucoma is a leading cause of blindness." | 5.36 | Melatonin: a novel neuroprotectant for the treatment of glaucoma. ( Belforte, NA; Chianelli, MS; de Zavalía, N; Keller Sarmiento, MI; Moreno, MC; Rosenstein, RE; Sande, PH, 2010) |
| "To evaluate the effect of a new nutritional supplement based on melatonin on the intraocular pressure (IOP) in normotensive subjects." | 5.34 | Effect of nutritional supplement based on melatonin on the intraocular pressure in normotensive subjects. ( Bodas-Romero, J; Carracedo-Rodríguez, G; Martínez-Águila, A; Pintor, J; Rodriguez-Pomar, C; Sanchez-Naves, J, 2020) |
| "Melatonin was measured by radioimmunoassay in several genetic strains of Japanese quail." | 5.28 | Melatonin reduction by lithium and albinism in quail and hamsters. ( Lauber, JK; Vriend, J, 1989) |
| "Melatonin significantly reduced the anxiety scores (median, interquartile range) from 5 and 5-3 to 3 and 2-4 after premedication and to 3 and 2-3 during surgery and to 0 and 0-1 postoperatively before discharge from the recovery room." | 5.17 | The effects of melatonin on anxiety and pain scores of patients, intraocular pressure, and operating conditions during cataract surgery under topical anesthesia. ( Khezri, MB; Merate, H, 2013) |
| "Melatonin significantly reduced the anxiety scores (median, interquartile range) from 5, 3." | 5.14 | Melatonin provides anxiolysis, enhances analgesia, decreases intraocular pressure, and promotes better operating conditions during cataract surgery under topical anesthesia. ( Ismail, SA; Mowafi, HA, 2009) |
| "We studied the effect of orally administered melatonin on intraocular pressure in humans." | 5.06 | Effect of melatonin on intraocular pressure. ( Krause, G; Lewy, AJ; Samples, JR, 1988) |
| "We aimed to compare the neuroprotective effects of brimonidine tartrate (BRT) and melatonin (MEL) on retinal ganglion cells (RGCs) in a rat glaucoma model." | 3.88 | Comparison of the neuroprotective effects of brimonidine tartrate and melatonin on retinal ganglion cells. ( Ciftci, F; Eyuboglu, S; Gumusel, A; Guzel, E; Marangoz, D; Seckin, I; Yalvac, I; Yilmaz, B, 2018) |
| " The synthesis of oxindole-based melatonin and 5-methoxycarbonylamino-N-acetyltryptamine (5-MCA-NAT) analogues was proposed and their ability to influence intraocular pressure (IOP) was studied in vivo." | 3.85 | Oxindole-based intraocular pressure reducing agents. ( Beznos, OV; Chesnokova, NB; Lozinskaya, NA; Volkova, MS; Zaryanova, EV; Zefirov, NS, 2017) |
| "To study the levels of melatonin in the aqueous humour of normotensive and hypertensive intraocular pressure (IOP) patients and to compare them to an animal model of glaucoma." | 3.85 | Elevated intraocular pressure increases melatonin levels in the aqueous humour. ( Alkozi, H; Carracedo, G; de Lara, MJ; Fonseca, B; Martinez-Aguila, A; Pintor, J; Sánchez-Naves, J, 2017) |
| "Melatonin is a pineal hormone that has a capacity to lower intraocular pressure; it exhibits neuroprotective and antioxidant properties that make it possible to use melatonin in the therapy of glaucoma." | 3.85 | [Novel agonists of melatonin receptors as promising hypotensive and neuroprotective agents for therapy of glaucoma]. ( Beznos, OV; Chesnokova, NB; Grigoryev, AV; Lozinskaya, NA; Volkova, MS; Zaryanova, EV; Zefirov, NA, 2017) |
| " Using both control C57BL/6J and glaucomatous DBA/2J mice as well as TonoLab tonometry, this study evaluated the effect of melatonin and 5-methoxycarbonylamino-N-acetyltryptamine (5-MCA-NAT) when glaucomatous pathology was fully established and compared pharmacological behavior in treated mice versus control mice." | 3.83 | Effect of Melatonin and 5-Methoxycarbonylamino-N-Acetyltryptamine on the Intraocular Pressure of Normal and Glaucomatous Mice. ( Fonseca, B; Martínez-Águila, A; Pérez de Lara, MJ; Pintor, J, 2016) |
| "We explored the melatonin influence on the level of amino acid neurotransmitters of the retina in glaucoma neuropathy in rats." | 3.79 | [Protective action of melatonin in experimental glaucoma in rats]. ( Mykheĭtseva, IM, 2013) |
| "Melatonin, a neurohormone secreted by the pineal gland, is able to modulate intraocular pressure (IOP)." | 3.79 | Polymeric nanoparticles augment the ocular hypotensive effect of melatonin in rabbits. ( Bucolo, C; Carbone, C; Drago, F; Musumeci, T; Pignatello, R; Puglisi, G, 2013) |
| "The present study was designed to determine the effects of melatonin and its receptor agonists on SNP-released nitric oxide (NO) and cGMP production in aqueous humor producing cells of the ciliary body because these effects may play a role in melatonin receptor-mediated regulation of intraocular pressure (IOP)." | 3.79 | Melatonin receptor agonist-induced reduction of SNP-released nitric oxide and cGMP production in isolated human non-pigmented ciliary epithelial cells. ( Dortch-Carnes, J; Tosini, G, 2013) |
| "In the search for new compounds to reduce intraocular pressure (IOP), with fewer side effects, we have found that agomelatine, a melatonin analogue, can reduce IOP being, therefore, interesting for the treatment of ocular hypertension and glaucoma." | 3.79 | Melatonin analogue agomelatine reduces rabbit's intraocular pressure in normotensive and hypertensive conditions. ( Bergua, A; Fonseca, B; Martínez-Águila, A; Pintor, J, 2013) |
| "Melatonin is currently considered a promising drug for glaucoma treatment because of its ocular hypotensive and neuroprotective effects." | 3.79 | Melatonin and its analog 5-methoxycarbonylamino-N-acetyltryptamine potentiate adrenergic receptor-mediated ocular hypotensive effects in rabbits: significance for combination therapy in glaucoma. ( Crooke, A; Huete-Toral, F; Martín-Gil, A; Martínez-Águila, A; Pintor, J, 2013) |
| " Among these modifications are alterations in insulin secretion, sympathetic activity, free fatty acids, lipid profile, melatonin, cortisol, electrolytes and catecholamines." | 3.77 | Impact of Ramadan fasting on intraocular pressure, visual acuity and refractive errors. ( Afarid, M; Akrami, A; Assadi, M; Beikzadeh, F; Larijani, B; Nabipour, I; Seidali, E; Seyedabadi, M, 2011) |
| "Melatonin, the MT(2) melatonin receptor agonist IIK7 [N-butanoyl-2-(2-methoxy-6H-isoindolo[2,1-a]indol-11-yl)ethanamine], and the putative MT(3) melatonin receptor agonist 5-MCA-NAT [5-methoxycarbonylamino-N-acetyltryptamine] have previously been shown to reduce intraocular pressure (IOP) in ocular normotensive rabbits." | 3.77 | Design of novel melatonin analogs for the reduction of intraocular pressure in normotensive rabbits. ( Alarma-Estrany, P; Guzman-Aranguez, A; Huete, F; Pelaez, T; Peral, A; Pintor, J; Plourde, R; Yerxa, B, 2011) |
| " We examined the ability of melatonin and the selective MT(3) receptor agonist, 5-methoxycarbonylamino-N-acetyltryptamine (5-MCA-NAT), to modify intraocular pressure in rabbits." | 3.71 | Involvement of melatonin MT(3) receptors in the regulation of intraocular pressure in rabbits. ( Hoyle, CH; Martin, L; Pelaez, T; Peral, A; Pintor, J, 2001) |
| " Here we describe three experiments which investigated: (i) the effects of sleep in five groups of subjects: glaucoma, suspect glaucoma, young high-normal IOP, old high-normal IOP groups and an elderly control group, (ii) the effect of exposure to bright light (2500 lux) during sleep on associated IOP changes, and (iii) the relationship between changes in IOP and plasma melatonin during sleep." | 3.68 | Investigation of parameters influencing intraocular pressure increases during sleep. ( Brown, B; Eyeson-Annan, M; Fletcher, T; Swann, PG; Wildsoet, C, 1993) |
| "Melatonin injected into the vortex vein of a rabbit eye produced an increase in intraocular pressure (IOP) which lasted for up to 5 h." | 3.68 | Effects of melatonin and haloperidol given via vortex vein on the intraocular pressure. ( Chiou, GC; Li, BH; Rohde, BH, 1993) |
| "It has been reported that diurnal changes in intraocular pressure (IOP) may be related to the fluctuation of melatonin levels in the eye." | 3.67 | Studies on the involvement of melatonergic mechanism in intraocular pressure regulation. ( Chiou, GC; McLaughlin, MA, 1984) |
| "The proposed role of melatonin as an endogenously synthesized modulator of intraocular pressure in the eye was investigated." | 3.67 | Existence and role of endogenous ocular melatonin. ( Chiou, LY; McLaughlin, MA; Rohde, BH, 1985) |
| "Melatonin is a promising substance to ameliorate glaucoma-associated compromised circadian rhythms, sleep, mood, and retinal cells function." | 3.01 | Melatonin mitigates disrupted circadian rhythms, lowers intraocular pressure, and improves retinal ganglion cells function in glaucoma. ( Astakhov, SY; Cornelissen, G; Gubin, D; Kabitskaya, Y; Kolomeichuk, S; Malishevskaya, T; Neroev, V; Weinert, D; Yuzhakova, N, 2021) |
| "Melatonin is a hormone secreted into the blood mainly from the pineal gland allowing the entrainment of the circadian rhythms of several biological functions." | 2.48 | Update in glaucoma medicinal chemistry: emerging evidence for the importance of melatonin analogues. ( Colligris, B; Crooke, A; Pintor, J, 2012) |
| "The treatment with melatonin significantly decreased clinical signs and prevented the reduction in IOP induced by LPS." | 1.38 | Therapeutic benefit of melatonin in experimental feline uveitis. ( Aba, MA; Del Sole, MJ; Fernandez, DC; Rosenstein, RE; Sande, PH; Sarmiento, MI, 2012) |
| "Glaucoma is a leading cause of blindness worldwide, characterized by retinal ganglion cell degeneration and damage to the optic nerve." | 1.37 | Effect of experimental glaucoma on the non-image forming visual system. ( Belforte, N; de Zavalía, N; Fernandez, DC; Golombek, DA; Lanzani, MF; Plano, SA; Rosenstein, RE; Salido, E; Sarmiento, MI, 2011) |
| "Glaucoma is a leading cause of blindness." | 1.36 | Melatonin: a novel neuroprotectant for the treatment of glaucoma. ( Belforte, NA; Chianelli, MS; de Zavalía, N; Keller Sarmiento, MI; Moreno, MC; Rosenstein, RE; Sande, PH, 2010) |
| "Glaucoma is an optic neuropathy in which retinal ganglion cells die probably through an apoptotic process." | 1.32 | Retinal oxidative stress induced by high intraocular pressure. ( Campanelli, J; Keller Sarmiento, MI; Moreno, MC; Rosenstein, RE; Sande, P; Sánez, DA, 2004) |
| "Melatonin was measured by radioimmunoassay in several genetic strains of Japanese quail." | 1.28 | Melatonin reduction by lithium and albinism in quail and hamsters. ( Lauber, JK; Vriend, J, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (16.33) | 18.7374 |
| 1990's | 6 (12.24) | 18.2507 |
| 2000's | 6 (12.24) | 29.6817 |
| 2010's | 22 (44.90) | 24.3611 |
| 2020's | 7 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Zaryanova, EV | 2 |
| Lozinskaya, NA | 2 |
| Beznos, OV | 2 |
| Volkova, MS | 2 |
| Chesnokova, NB | 2 |
| Zefirov, NS | 1 |
| Giannetto, C | 1 |
| Rajaei, SM | 1 |
| Abdous, A | 1 |
| Ostadhasan, H | 1 |
| Alagha, HE | 1 |
| Faghihi, H | 1 |
| Piccione, G | 1 |
| Omidi, R | 1 |
| Fazio, F | 1 |
| Nilsen, NG | 1 |
| Gilson, SJ | 1 |
| Pedersen, HR | 1 |
| Hagen, LA | 1 |
| Knoblauch, K | 1 |
| Baraas, RC | 1 |
| Sane, S | 1 |
| Motarjemizadeh, Q | 1 |
| Komilzhonovich, IN | 1 |
| Abdelbasset, WK | 1 |
| Zaman, GS | 1 |
| Suksatan, W | 1 |
| Morwati, S | 1 |
| Haki, BK | 1 |
| Rahmani, N | 1 |
| Golabi, P | 1 |
| Mahmodi, H | 1 |
| Alkozi, HA | 1 |
| Navarro, G | 1 |
| Franco, R | 1 |
| Pintor, J | 10 |
| Carracedo-Rodríguez, G | 1 |
| Martínez-Águila, A | 6 |
| Rodriguez-Pomar, C | 1 |
| Bodas-Romero, J | 1 |
| Sanchez-Naves, J | 2 |
| Martín-Gil, A | 2 |
| Carpena-Torres, C | 1 |
| Pastrana, C | 1 |
| Carracedo, G | 2 |
| Gubin, D | 1 |
| Neroev, V | 1 |
| Malishevskaya, T | 1 |
| Cornelissen, G | 1 |
| Astakhov, SY | 1 |
| Kolomeichuk, S | 1 |
| Yuzhakova, N | 1 |
| Kabitskaya, Y | 1 |
| Weinert, D | 1 |
| Marangoz, D | 1 |
| Guzel, E | 1 |
| Eyuboglu, S | 1 |
| Gumusel, A | 1 |
| Seckin, I | 1 |
| Ciftci, F | 1 |
| Yilmaz, B | 1 |
| Yalvac, I | 1 |
| Kim, JY | 1 |
| Jeong, AR | 1 |
| Chin, HS | 1 |
| Kim, NR | 1 |
| Visser, HE | 1 |
| Dees, DD | 1 |
| Millichamp, NJ | 1 |
| Vallone, LV | 1 |
| Scott, EM | 1 |
| Khezri, MB | 1 |
| Merate, H | 1 |
| Crooke, A | 3 |
| Huete-Toral, F | 1 |
| Mykheĭtseva, IM | 1 |
| Quinteros, D | 1 |
| Vicario-de-la-Torre, M | 1 |
| Andrés-Guerrero, V | 1 |
| Palma, S | 1 |
| Allemandi, D | 1 |
| Herrero-Vanrell, R | 1 |
| Molina-Martínez, IT | 1 |
| Leonardi, A | 1 |
| Bucolo, C | 2 |
| Drago, F | 2 |
| Salomone, S | 1 |
| Pignatello, R | 2 |
| Pescosolido, N | 1 |
| Gatto, V | 1 |
| Stefanucci, A | 1 |
| Rusciano, D | 1 |
| Fonseca, B | 3 |
| Pérez de Lara, MJ | 1 |
| Alkozi, H | 1 |
| de Lara, MJ | 1 |
| Zefirov, NA | 1 |
| Grigoryev, AV | 1 |
| Alarma-Estrany, P | 2 |
| Mediero, A | 1 |
| Peláez, T | 3 |
| Ismail, SA | 1 |
| Mowafi, HA | 1 |
| Belforte, NA | 1 |
| Moreno, MC | 3 |
| de Zavalía, N | 3 |
| Sande, PH | 2 |
| Chianelli, MS | 1 |
| Keller Sarmiento, MI | 3 |
| Rosenstein, RE | 6 |
| Guzman-Aranguez, A | 1 |
| Huete, F | 1 |
| Peral, A | 2 |
| Plourde, R | 1 |
| Yerxa, B | 1 |
| Plano, SA | 1 |
| Fernandez, DC | 2 |
| Lanzani, MF | 1 |
| Salido, E | 1 |
| Belforte, N | 1 |
| Sarmiento, MI | 2 |
| Golombek, DA | 1 |
| Assadi, M | 1 |
| Akrami, A | 1 |
| Beikzadeh, F | 1 |
| Seyedabadi, M | 1 |
| Nabipour, I | 1 |
| Larijani, B | 1 |
| Afarid, M | 1 |
| Seidali, E | 1 |
| Del Sole, MJ | 1 |
| Aba, MA | 1 |
| Colligris, B | 1 |
| Musumeci, T | 1 |
| Carbone, C | 1 |
| Puglisi, G | 1 |
| Dortch-Carnes, J | 1 |
| Tosini, G | 1 |
| Bergua, A | 1 |
| Campanelli, J | 1 |
| Sande, P | 2 |
| Sánez, DA | 1 |
| Marcos, HA | 1 |
| Lundmark, PO | 1 |
| Pandi-Perumal, SR | 1 |
| Srinivasan, V | 1 |
| Cardinali, DP | 1 |
| Chiou, GC | 3 |
| McLaughlin, MA | 2 |
| Osborne, NN | 1 |
| Wildsoet, C | 1 |
| Eyeson-Annan, M | 1 |
| Brown, B | 3 |
| Swann, PG | 1 |
| Fletcher, T | 1 |
| Rohde, BH | 2 |
| Li, BH | 1 |
| Kiuchi, Y | 1 |
| Mockovak, ME | 1 |
| Gregory, DS | 1 |
| Liu, JH | 2 |
| Shieh, BE | 1 |
| Martin, L | 1 |
| Hoyle, CH | 1 |
| Dacus, AC | 1 |
| Lauber, JK | 1 |
| Vriend, J | 1 |
| Burton, P | 1 |
| Mann, S | 1 |
| Parisi, A | 1 |
| Samples, JR | 2 |
| Krause, G | 1 |
| Lewy, AJ | 2 |
| Sack, RL | 1 |
| Miller, LS | 1 |
| Hoban, TM | 1 |
| Singer, CM | 1 |
| Krauss, GL | 1 |
| Frampton, P | 1 |
| Da Rin, D | 1 |
| Chiou, LY | 2 |
| Aimoto, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Premedication With Melatonin vs. Placebo in Patients Undergoing Interventional Pain Procedure[NCT02415309] | Phase 3 | 25 participants (Actual) | Interventional | 2016-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for melatonin and Intraocular Pressure
| Article | Year |
|---|---|
Melatonin and the control of intraocular pressure.
Topics: Animals; Aqueous Humor; Glaucoma; Humans; Intraocular Pressure; Melatonin | 2020 |
Influence of Circadian Rhythm in the Eye: Significance of Melatonin in Glaucoma.
Topics: Animals; Circadian Rhythm; Dry Eye Syndromes; Glaucoma; Humans; Intraocular Pressure; Melatonin; Myo | 2021 |
Update in glaucoma medicinal chemistry: emerging evidence for the importance of melatonin analogues.
Topics: Animals; Chemistry, Pharmaceutical; Glaucoma; Humans; Intraocular Pressure; Melatonin; Molecular Str | 2012 |
Melatonin in the eye: implications for glaucoma.
Topics: Animals; Antioxidants; Eye; Glaucoma; Humans; Intraocular Pressure; Melatonin; Oxidative Stress; Rec | 2007 |
Serotonin and melatonin in the iris/ciliary processes and their involvement in intraocular pressure.
Topics: Animals; Ciliary Body; Humans; Intraocular Pressure; Iris; Melatonin; Rabbits; Receptors, Cell Surfa | 1994 |
8 trials available for melatonin and Intraocular Pressure
| Article | Year |
|---|---|
Effects of long-term oral administration of melatonin on tear production, intraocular pressure, and tear and serum melatonin concentrations in healthy dogs.
Topics: Administration, Oral; Animals; Dogs; Intraocular Pressure; Male; Melatonin; Tears; Tonometry, Ocular | 2022 |
The Effect of Melatonin on Analgesia, Anxiety, and Intraocular Pressure (IOP) in Cataract Surgery Under Topical Anesthesia.
Topics: Analgesia; Anesthesia, Local; Anxiety; Cataract; Double-Blind Method; Humans; Intraocular Pressure; | 2023 |
Effect of nutritional supplement based on melatonin on the intraocular pressure in normotensive subjects.
Topics: Adult; Antioxidants; Female; Follow-Up Studies; Healthy Volunteers; Humans; Intraocular Pressure; Ma | 2020 |
Melatonin mitigates disrupted circadian rhythms, lowers intraocular pressure, and improves retinal ganglion cells function in glaucoma.
Topics: Aged; Circadian Rhythm; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Male; Melatonin; | 2021 |
Effect of orally administered melatonin on intraocular pressure of ophthalmologically normal dogs.
Topics: Administration, Oral; Animals; Circadian Rhythm; Cross-Over Studies; Dogs; Double-Blind Method; Fema | 2019 |
The effects of melatonin on anxiety and pain scores of patients, intraocular pressure, and operating conditions during cataract surgery under topical anesthesia.
Topics: Administration, Sublingual; Adult; Aged; Aged, 80 and over; Anesthesia, Local; Anxiety; Central Nerv | 2013 |
Melatonin provides anxiolysis, enhances analgesia, decreases intraocular pressure, and promotes better operating conditions during cataract surgery under topical anesthesia.
Topics: Administration, Oral; Administration, Topical; Aged; Aged, 80 and over; Analgesics; Anesthetics, Loc | 2009 |
Effect of melatonin on intraocular pressure.
Topics: Administration, Oral; Circadian Rhythm; Humans; Intraocular Pressure; Light; Melatonin | 1988 |
36 other studies available for melatonin and Intraocular Pressure
| Article | Year |
|---|---|
Oxindole-based intraocular pressure reducing agents.
Topics: Crystallography, X-Ray; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Indoles; Intrao | 2017 |
Seasonal Variation in Diurnal Rhythms of the Human Eye: Implications for Continuing Ocular Growth in Adolescents and Young Adults.
Topics: Adolescent; Choroid; Circadian Rhythm; Humans; Intraocular Pressure; Melatonin; Seasons; Young Adult | 2022 |
Comparison of the neuroprotective effects of brimonidine tartrate and melatonin on retinal ganglion cells.
Topics: Animals; Antioxidants; Apoptosis; Brimonidine Tartrate; Disease Models, Animal; Glaucoma; Intraocula | 2018 |
Melatonin Levels in Patients With Primary Open-angle Glaucoma With High or Low Intraocular Pressure.
Topics: Aged; Creatinine; Enzyme-Linked Immunosorbent Assay; Female; Glaucoma, Open-Angle; Humans; Intraocul | 2019 |
Melatonin and its analog 5-methoxycarbonylamino-N-acetyltryptamine potentiate adrenergic receptor-mediated ocular hypotensive effects in rabbits: significance for combination therapy in glaucoma.
Topics: Adrenergic Agonists; Adrenergic alpha-2 Receptor Agonists; Adrenergic beta-Antagonists; Animals; Cel | 2013 |
[Protective action of melatonin in experimental glaucoma in rats].
Topics: Animals; Antioxidants; Aspartic Acid; Chromatography, Ion Exchange; Epinephrine; gamma-Aminobutyric | 2013 |
Hybrid formulations of liposomes and bioadhesive polymers improve the hypotensive effect of the melatonin analogue 5-MCA-NAT in rabbit eyes.
Topics: Adhesives; Animals; Antihypertensive Agents; Chemistry, Pharmaceutical; Drug Liberation; Hydrogen-Io | 2014 |
Cationic solid lipid nanoparticles enhance ocular hypotensive effect of melatonin in rabbit.
Topics: Animals; Drug Liberation; Intraocular Pressure; Lipids; Male; Melatonin; Nanoparticles; Palmitic Aci | 2015 |
Oral treatment with the melatonin agonist agomelatine lowers the intraocular pressure of glaucoma patients.
Topics: Acetamides; Administration, Oral; Aged; Antihypertensive Agents; Female; Glaucoma, Open-Angle; Human | 2015 |
Effect of Melatonin and 5-Methoxycarbonylamino-N-Acetyltryptamine on the Intraocular Pressure of Normal and Glaucomatous Mice.
Topics: Animals; Dose-Response Relationship, Drug; Glaucoma; Intraocular Pressure; Melatonin; Mice; Mice, In | 2016 |
Elevated intraocular pressure increases melatonin levels in the aqueous humour.
Topics: Adult; Aged; Aged, 80 and over; Animals; Aqueous Humor; Biomarkers; Chromatography, High Pressure Li | 2017 |
[Novel agonists of melatonin receptors as promising hypotensive and neuroprotective agents for therapy of glaucoma].
Topics: Animals; Antioxidants; Drug Design; Gene Expression; Glaucoma; Indoles; Intraocular Pressure; Ligand | 2017 |
Sympathetic nervous system modulates the ocular hypotensive action of MT2-melatonin receptors in normotensive rabbits.
Topics: 1-Methyl-3-isobutylxanthine; Administration, Topical; Adrenergic beta-Agonists; Albuterol; Animals; | 2008 |
Melatonin: a novel neuroprotectant for the treatment of glaucoma.
Topics: Animals; Arginine; gamma-Aminobutyric Acid; Glaucoma; Glutamate Decarboxylase; Glutamic Acid; Histoc | 2010 |
Design of novel melatonin analogs for the reduction of intraocular pressure in normotensive rabbits.
Topics: Animals; Dose-Response Relationship, Drug; Drug Design; Eye; Glaucoma; Intraocular Pressure; Isoindo | 2011 |
Effect of experimental glaucoma on the non-image forming visual system.
Topics: Animals; Anterior Eye Segment; Blotting, Western; Cell Count; Chondroitin Sulfates; Eye; Glaucoma; I | 2011 |
Impact of Ramadan fasting on intraocular pressure, visual acuity and refractive errors.
Topics: Adult; Catecholamines; Electrolytes; Fasting; Fatty Acids, Nonesterified; Humans; Hydrocortisone; In | 2011 |
Therapeutic benefit of melatonin in experimental feline uveitis.
Topics: Analysis of Variance; Animals; Cats; Electroretinography; Histocytochemistry; Intraocular Pressure; | 2012 |
Polymeric nanoparticles augment the ocular hypotensive effect of melatonin in rabbits.
Topics: Administration, Ophthalmic; Animals; Delayed-Action Preparations; Drug Carriers; Drug Compounding; D | 2013 |
Melatonin receptor agonist-induced reduction of SNP-released nitric oxide and cGMP production in isolated human non-pigmented ciliary epithelial cells.
Topics: Aqueous Humor; Cells, Cultured; Ciliary Body; Colorimetry; Cyclic GMP; Epithelial Cells; Humans; Imm | 2013 |
Melatonin analogue agomelatine reduces rabbit's intraocular pressure in normotensive and hypertensive conditions.
Topics: Acetamides; Animals; Dose-Response Relationship, Drug; Intraocular Pressure; Melatonin; Ocular Hyper | 2013 |
Retinal oxidative stress induced by high intraocular pressure.
Topics: Animals; Antioxidants; Free Radicals; Glaucoma; Glutathione; Hyaluronic Acid; Intraocular Pressure; | 2004 |
Effect of glaucoma on the retinal glutamate/glutamine cycle activity.
Topics: Animals; Glaucoma; Glutamate-Ammonia Ligase; Glutamic Acid; Glutaminase; Glutamine; Hyaluronic Acid; | 2005 |
Studies on the involvement of melatonergic mechanism in intraocular pressure regulation.
Topics: Animals; Biomechanical Phenomena; Circadian Rhythm; Female; Fenclonine; Intraocular Pressure; Melato | 1984 |
Investigation of parameters influencing intraocular pressure increases during sleep.
Topics: Adult; Age Factors; Aged; Female; Glaucoma; Humans; Intraocular Pressure; Light; Male; Melatonin; Mi | 1993 |
Effects of melatonin and haloperidol given via vortex vein on the intraocular pressure.
Topics: Analgesics; Animals; Ciliary Body; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Enkephalins; Female; Haloper | 1993 |
Melatonin does not increase IOP significantly in rabbits.
Topics: Administration, Topical; Animals; Aqueous Humor; Circadian Rhythm; Infusions, Intra-Arterial; Inject | 1993 |
Suprachiasmatic nucleus in the neural circuitry for the circadian elevation of intraocular pressure in rabbits.
Topics: Animals; Aqueous Humor; Circadian Rhythm; Intraocular Pressure; Light; Male; Melatonin; Neural Pathw | 1995 |
Involvement of melatonin MT(3) receptors in the regulation of intraocular pressure in rabbits.
Topics: Animals; Dose-Response Relationship, Drug; Intraocular Pressure; Male; Melatonin; Rabbits; Receptors | 2001 |
Endogenous hormonal changes and circadian elevation of intraocular pressure.
Topics: Animals; Aqueous Humor; Catecholamines; Chromatography, High Pressure Liquid; Circadian Rhythm; Cort | 1991 |
Melatonin reduction by lithium and albinism in quail and hamsters.
Topics: Albinism; Animals; Bird Diseases; Chlorides; Coturnix; Cricetinae; Eye; Intraocular Pressure; Lithiu | 1989 |
Fluctuations in intra-ocular pressure with sleep: II. Time course of IOP decrease after waking from sleep.
Topics: Adolescent; Adult; Data Interpretation, Statistical; Female; Humans; Intraocular Pressure; Male; Mel | 1988 |
The use of plasma melatonin levels and light in the assessment and treatment of chronobiologic sleep and mood disorders.
Topics: Biological Clocks; Humans; Intraocular Pressure; Light; Melatonin; Mood Disorders; Phototherapy; Sea | 1986 |
Diurnal variation of intraocular pressure and the overriding effects of sleep.
Topics: Adolescent; Adult; Circadian Rhythm; Female; Humans; Intraocular Pressure; Male; Melatonin; Posture; | 1987 |
Existence and role of endogenous ocular melatonin.
Topics: Animals; Cats; Chickens; Circadian Rhythm; Female; Intraocular Pressure; Male; Melatonin; Pineal Gla | 1985 |
Melatonergic involvement in diurnal changes of intraocular pressure in rabbit eyes.
Topics: Acetyltransferases; Animals; Choline O-Acetyltransferase; Eye; Intraocular Pressure; Melatonin; Rabb | 1985 |